NASDAQ:NBIX - Neurocrine Biosciences Stock Price, Price Target & More

Neurocrine Biosciences trades on the NASDAQ under the ticker symbol "NBIX."

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) posted its earnings results on Monday, April, 30th. The company reported ($0.47) EPS for the quarter, missing analysts' consensus estimates of ($0.29) by $0.18. The company earned $71.08 million during the quarter, compared to the consensus estimate of $65.17 million. Neurocrine Biosciences had a negative return on equity of 29.67% and a negative net margin of 45.56%. During the same period last year, the company posted ($0.90) EPS. View Neurocrine Biosciences' Earnings History.

Neurocrine Biosciences is scheduled to release their next quarterly earnings announcement on Tuesday, July, 31st 2018. View Earnings Estimates for Neurocrine Biosciences.

13 brokerages have issued 1-year price targets for Neurocrine Biosciences' shares. Their predictions range from $79.00 to $127.00. On average, they expect Neurocrine Biosciences' stock price to reach $104.6154 in the next year. This suggests a possible upside of 1.1% from the stock's current price. View Analyst Ratings for Neurocrine Biosciences.

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neurocrine Biosciences in the last year. There are currently 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Some companies that are related to Neurocrine Biosciences include NOVOZYMES A/S/S (NVZMY), Seattle Genetics (SGEN), bluebird bio (BLUE), Qiagen (QGEN), AveXis (AVXS), BIO-TECHNE (TECH), Ablynx (ABLYF), China Biologic Products (CBPO), argenx (ARGX), Spark Therapeutics (ONCE), Aerie Pharmaceuticals (AERI), Crispr Therapeutics (CRSP), Halozyme Therapeutics (HALO), Regenxbio (RGNX) and Momenta Pharmaceuticals (MNTA).

Press coverage about NBIX stock has been trending somewhat positive recently, Accern reports. Accern identifies negative and positive news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Neurocrine Biosciences earned a news impact score of 0.13 on Accern's scale. They also assigned news stories about the company an impact score of 46.08 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

Neurocrine Biosciences' stock is owned by many different of retail and institutional investors. Top institutional investors include Handelsbanken Fonder AB (0.18%), Boston Advisors LLC (0.15%), Mckinley Capital Management LLC Delaware (0.14%), Fred Alger Management Inc. (0.07%), Fisher Asset Management LLC (0.03%) and Amalgamated Bank (0.02%). Company insiders that own Neurocrine Biosciences stock include Christopher Flint Obrien, Corinne H Nevinny, Darin Lippoldt, Dimitri E Grigoriadis, Eric Benevich, Gary A Lyons, Haig P Bozigian, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Stephen A Sherwin, Timothy P Coughlin and William H Rastetter. View Institutional Ownership Trends for Neurocrine Biosciences.

NBIX stock was sold by a variety of institutional investors in the last quarter, including Handelsbanken Fonder AB and NN Investment Partners Holdings N.V.. Company insiders that have sold Neurocrine Biosciences company stock in the last year include Christopher Flint Obrien, Corinne H Nevinny, Darin Lippoldt, Dimitri E Grigoriadis, Eric Benevich, Gary A Lyons, Haig P Bozigian, Kevin Charles Gorman, Kyle Gano, Stephen A Sherwin and William H Rastetter. View Insider Buying and Selling for Neurocrine Biosciences.

NBIX stock was purchased by a variety of institutional investors in the last quarter, including Boston Advisors LLC, Fisher Asset Management LLC, Fred Alger Management Inc., Sit Investment Associates Inc., Highland Capital Management LLC, Rockland Trust Co., State of Alaska Department of Revenue and Amalgamated Bank. View Insider Buying and Selling for Neurocrine Biosciences.

Shares of NBIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of NBIX stock can currently be purchased for approximately $103.43.

Neurocrine Biosciences has a market capitalization of $9.30 billion and generates $161.63 million in revenue each year. The company earns $-142,540,000.00 in net income (profit) each year or ($1.62) on an earnings per share basis. Neurocrine Biosciences employs 400 workers across the globe.

Neurocrine Biosciences' mailing address is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. The company can be reached via phone at 858-617-7600 or via email at [email protected]